MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 56 filers reported holding MERSANA THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,115 | -99.7% | 878 | -99.1% | 0.00% | -100.0% |
| Q2 2023 | $328,222 | +334.1% | 99,764 | +442.3% | 0.00% | – |
| Q1 2023 | $75,611 | -44.9% | 18,397 | -21.4% | 0.00% | – |
| Q4 2022 | $137,176 | -4.7% | 23,409 | +9.4% | 0.00% | – |
| Q3 2022 | $144,000 | +620.0% | 21,402 | +377.3% | 0.00% | – |
| Q2 2022 | $20,000 | -91.1% | 4,484 | -92.1% | 0.00% | – |
| Q1 2022 | $224,000 | +26.6% | 56,458 | +743.9% | 0.00% | – |
| Q4 2020 | $177,000 | -45.5% | 6,690 | -61.7% | 0.00% | -100.0% |
| Q3 2020 | $325,000 | -73.0% | 17,485 | -66.2% | 0.00% | -66.7% |
| Q2 2020 | $1,204,000 | +122.6% | 51,699 | -43.9% | 0.00% | +200.0% |
| Q1 2020 | $541,000 | +1832.1% | 92,222 | +410.4% | 0.00% | – |
| Q3 2019 | $28,000 | -50.0% | 18,069 | +30.0% | 0.00% | – |
| Q2 2019 | $56,000 | +9.8% | 13,900 | +41.8% | 0.00% | – |
| Q1 2019 | $51,000 | -93.3% | 9,800 | -77.1% | 0.00% | -100.0% |
| Q2 2018 | $766,000 | +13.3% | 42,858 | 0.0% | 0.00% | +100.0% |
| Q1 2018 | $676,000 | – | 42,858 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 8,663,673 | $40,026,000 | 4.69% |
| Opaleye Management Inc. | 1,047,000 | $4,837,000 | 2.18% |
| Sarissa Capital Management LP | 4,299,297 | $19,863,000 | 2.00% |
| Decheng Capital Management III (Cayman), LLC | 904,268 | $4,178,000 | 1.58% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 850,000 | $3,927,000 | 1.21% |
| Orbimed Advisors | 9,011,437 | $41,633,000 | 0.75% |
| Avoro Capital Advisors LLC | 7,550,000 | $34,881,000 | 0.69% |
| Rock Springs Capital Management LP | 4,075,958 | $18,831,000 | 0.55% |
| Artal Group S.A. | 2,200,000 | $10,164,000 | 0.54% |
| DAFNA Capital Management LLC | 406,763 | $1,879,000 | 0.51% |